616 related articles for article (PubMed ID: 17609808)
21. Clinical experience: practical management of five patients with cutaneous T-cell lymphoma (CTCL)-related symptoms.
Dummer R; Foss F; Dreno B; Bagot M
Semin Oncol; 2006 Feb; 33(1 Suppl 3):S26-32. PubMed ID: 16516673
[TBL] [Abstract][Full Text] [Related]
22. Extracorporeal photochemotherapy in patients with cutaneous T-cell lymphoma: is clinical response predictable?
Rao V; Ryggen K; Aarhaug M; Dai HY; Jørstad S; Moen T
J Eur Acad Dermatol Venereol; 2006 Oct; 20(9):1100-7. PubMed ID: 16987266
[TBL] [Abstract][Full Text] [Related]
23. The optimal use of bexarotene in cutaneous T-cell lymphoma.
Gniadecki R; Assaf C; Bagot M; Dummer R; Duvic M; Knobler R; Ranki A; Schwandt P; Whittaker S
Br J Dermatol; 2007 Sep; 157(3):433-40. PubMed ID: 17553039
[TBL] [Abstract][Full Text] [Related]
24. Therapeutic approaches in cutaneous lymphoma.
Jörg B; Kerl H; Thiers BH; Bröcker EB; Burg G
Dermatol Clin; 1994 Apr; 12(2):433-41. PubMed ID: 8045054
[TBL] [Abstract][Full Text] [Related]
25. Extracorporeal Photopheresis in the Treatment of Mycosis Fungoides and Sézary Syndrome.
Zic JA
Dermatol Clin; 2015 Oct; 33(4):765-76. PubMed ID: 26433848
[TBL] [Abstract][Full Text] [Related]
26. Management of cutaneous T-Cell lymphoma patients with extracorporeal photopheresis. The Hellenic experience.
Siakantaris MP; Tsirigotis P; Stavroyianni N; Argyropoulos KV; Girkas K; Pappa V; Chondropoulos S; Papadavid E; Sakellari I; Anagnostopoulos A; Antoniou C; Dervenoulas J
Transfus Apher Sci; 2012 Apr; 46(2):189-93. PubMed ID: 22178592
[TBL] [Abstract][Full Text] [Related]
27. Safety of a new, single, integrated, closed photopheresis system in patients with cutaneous T-cell lymphoma.
Bisaccia E; Vonderheid EC; Geskin L
Br J Dermatol; 2009 Jul; 161(1):167-9. PubMed ID: 19298276
[TBL] [Abstract][Full Text] [Related]
28. Extracorporeal photopheresis for the treatment of erythrodermic cutaneous T-cell lymphoma: a single center clinical experience with long-term follow-up data and a brief overview of the literature.
Quaglino P; Knobler R; Fierro MT; Savoia P; Marra E; Fava P; Bernengo MG
Int J Dermatol; 2013 Nov; 52(11):1308-18. PubMed ID: 23786842
[TBL] [Abstract][Full Text] [Related]
29. [Update on extracorporeal photopheresis].
Just U; Knobler R
Hautarzt; 2015 Nov; 66(11):804-9. PubMed ID: 26431837
[TBL] [Abstract][Full Text] [Related]
30. Serum soluble interleukin 2 receptor levels in erythrodermic cutaneous T-cell lymphoma correlate with response to photopheresis-based treatment.
Goldman BD; Oh SK; Davis BE; Kadin ME; Poiesz BJ; Koh HK
Arch Dermatol; 1993 Sep; 129(9):1166-70. PubMed ID: 8363402
[TBL] [Abstract][Full Text] [Related]
31. Monitoring the decrease of circulating malignant T cells in cutaneous T-cell lymphoma during photopheresis and interferon therapy.
Ferenczi K; Yawalkar N; Jones D; Kupper TS
Arch Dermatol; 2003 Jul; 139(7):909-13. PubMed ID: 12873887
[TBL] [Abstract][Full Text] [Related]
32. Extracorporeal photopheresis for the treatment of cutaneous T-cell lymphoma--the Düsseldorf and Munich experience.
Prinz B; Behrens W; Hölzle E; Plewig G
Arch Dermatol Res; 1995; 287(7):621-6. PubMed ID: 8534123
[TBL] [Abstract][Full Text] [Related]
33. Psoralen plus UVA vs. UVB-311 nm for the treatment of lichen planus.
Wackernagel A; Legat FJ; Hofer A; Quehenberger F; Kerl H; Wolf P
Photodermatol Photoimmunol Photomed; 2007 Feb; 23(1):15-9. PubMed ID: 17254030
[TBL] [Abstract][Full Text] [Related]
34. Photopheresis in cutaneous T-cell lymphoma: five-year experience.
Crovetti G; Carabelli A; Berti E; Guizzardi M; Fossati S; De Filippo C; Bertani E
Int J Artif Organs; 2000 Jan; 23(1):55-62. PubMed ID: 12118838
[TBL] [Abstract][Full Text] [Related]
35. Extracorporeal photopheresis: past, present, and future.
Knobler R; Barr ML; Couriel DR; Ferrara JL; French LE; Jaksch P; Reinisch W; Rook AH; Schwarz T; Greinix H
J Am Acad Dermatol; 2009 Oct; 61(4):652-65. PubMed ID: 19665258
[TBL] [Abstract][Full Text] [Related]
36. 75% Complete Response and 15% Partial Response to Extracorporeal Photopheresis Combined With Other Therapies in Resistant Early Stage Cutaneous T-Cell Lymphoma.
Seremet S; Abhyankar S; Herd TJ; Aires D
J Drugs Dermatol; 2016 Oct; 15(10):1212-1216. PubMed ID: 27741338
[TBL] [Abstract][Full Text] [Related]
37. [The application of photopheresis in the therapy of cancerous and autoimmune diseases].
Dall'Amico R; Zacchello G; Heald P
Recenti Prog Med; 1991 May; 82(5):294-9. PubMed ID: 1887157
[TBL] [Abstract][Full Text] [Related]
38. [Extracorporeal photochemotherapy for treatment of clonal T cell proliferations].
Plumas J; Drillat P; Jacob MC; Richard MJ; Favrot MC
Bull Cancer; 2003; 90(8-9):763-70. PubMed ID: 14609767
[TBL] [Abstract][Full Text] [Related]
39. Extracorporeal photopheresis reduces the number of mononuclear cells that produce pro-inflammatory cytokines, when tested ex-vivo.
Bladon J; Taylor P
J Clin Apher; 2002; 17(4):177-82. PubMed ID: 12494410
[TBL] [Abstract][Full Text] [Related]
40. Treatment of cutaneous T-cell lymphoma: an update.
Young JW
J Am Osteopath Assoc; 1993 May; 93(5):591-8, 603. PubMed ID: 8314721
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
